---
title: "vTv Therapeutics Inc. (VTVT.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/VTVT.US.md"
symbol: "VTVT.US"
name: "vTv Therapeutics Inc."
industry: "Biotechnology"
datetime: "2026-05-20T09:09:25.347Z"
locales:
  - [en](https://longbridge.com/en/quote/VTVT.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/VTVT.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/VTVT.US.md)
---

# vTv Therapeutics Inc. (VTVT.US)

## Company Overview

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [vtvtherapeutics.com](https://vtvtherapeutics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: B (0.28)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 50 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 216600.00% |  |
| Net Profit YoY | 112.05% |  |
| P/B Ratio | 1.60 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 143730278.55 |  |
| Revenue | 36839000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 4.60% | C |
| Profit Margin | 6.11% | B |
| Gross Margin | 75.63% | A |
| Revenue YoY | 216600.00% | A |
| Net Profit YoY | 112.05% | A |
| Total Assets YoY | 208.53% | A |
| Net Assets YoY | 911.12% | A |
| Cash Flow Margin | -462.43% | E |
| OCF YoY | 216600.00% | A |
| Turnover | 0.56 | C |
| Gearing Ratio | 8.96% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - vTv Therapeutics Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "216600.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "112.05%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.60",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "143730278.55",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "36839000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "4.60%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "6.11%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "75.63%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "216600.00%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "112.05%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "208.53%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "911.12%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-462.43%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "216600.00%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.56",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "8.96%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 63.82 | 53/386 | - | - | - |
| PB | 1.60 | 155/386 | 42.13 | 5.20 | 1.99 |
| PS (TTM) | 3.90 | 87/386 | 8796.22 | 8112.81 | 6552.32 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **6**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 36.49 |
| Highest Target | 67.00 |
| Lowest Target | 44.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/VTVT.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/VTVT.US/norm.md)
- [Related News](https://longbridge.com/en/quote/VTVT.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/VTVT.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**